Nifedipine
Brand names: Procardia Xl, Nifedipine, Nifedipine Er
At a glance
- Medicare prescriptions, 2024
- 3,042,416
- Medicare drug cost
- $77.7M
- Average cost per prescription
- $25.55
- Clinicians who prescribed it
- 88,119
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II.
From the FDA-approved prescribing information (label dated January 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 28.3%
- Family Medicine 22.8%
- Nurse Practitioners 14.3%
- Cardiology 10.2%
- Nephrology (Kidney) 9.8%
- Interventional Cardiology 3.6%
- Physician Assistants 3.5%
- General Practice 2.4%
- Geriatric Medicine 1.6%
- Hospitalist 0.7%
- Rheumatology 0.3%
- Cardiac Electrophysiology 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 17% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +44%
- Georgia +36%
- Nevada +35%
- Texas +34%
- Maryland +30%
- Massachusetts (smallest change) −15%
- Rhode Island (smallest change) −15%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Avpak
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | pink round tablet, 9 mm | KU 260 |
| 60 mg | pink round tablet, 10 mm | KU 261 |
| 90 mg | pink round tablet, 12 mm | KU 262 |
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | pink round tablet, 9 mm | KU 260 |
| 60 mg | pink round tablet, 10 mm | KU 261 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | pink round tablet, 10 mm | KU 261 |
Pfizer Laboratories Div Pfizer Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | pink round tablet, 9 mm | PROCARDIA XL 30 |
| 60 mg | pink round tablet, 10 mm | PROCARDIA XL 60 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Jul 2021 · The Harvard Drug Group · Class II
Failed Dissolution Specification: Out of specification for dissolution during routine stability testing.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.